 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17):

Slides:

Advertisements

Similar presentations

Case # 1 Dr. Laura Lamps A 32 year old Caucasian man presented to the Hepatology Clinic after he was found to have elevated transaminases during a routine.

Advertisements

TREATMENT Coagulopathy of Liver Failure. Fresh Frozen Plasma – Most effective way to correct hemostasis in patients with liver failure – Infusion (5-10mL/kg)

Drug Calculations CWFS F1 Programme Safe Prescribing Module

Topic 3 Math/Drugs Calculations. IV Giving Sets Generally there are 2 types of giving sets in use and they deliver drops of different sizes Blood giving.

Advanced Adult Intravenous Calculations

Selected Clinical Calculations

Switch to ATV + r-containing regimen - SWAN - SLOAT.

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-I.

Body Surface Area and Advanced Pediatric Calculations

Dosages Based on Body Surface Area (BSA)

IV Flow Rates –BASED ON BODY WEIGHT

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I Phase 3 Treatment Naïve Feld JJ, et.

BCIRG006 - Randomized Phase III Trial Comparing AC-T vs AC-TH vs TCH in HER2 Positive Node Positive or High Risk Node Negative Breast Cancer Initial efficacy.

ProCalc Nsg 231 Calculating IV Drug Dose based on Weight Example 1 Your patient’s current weight is 22 lbs. Dopamine is to be infused at 10 mcg/kg/minute.

7.1 Interpreting Labels Label InfoMeaning 25 mg/mlThis ratio tells the amount of medication in each ml of solution 1:4Ratios written this way always mean.

Introduction to Prescribing - Part 2 3 rd year Medical Students.

Drug Administration DRUG DOSE CALCULATION EMS 353LECTURE 11

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 9: Special Types of Intravenous Calculations.

Calculating Pediatric Dosage

Drug Treatment of Metastatic Breast Cancer

E.R. Gardner, 1 William D. Figg, 1 Marybeth S. Hughes 2 and James F. Pingpank 2 1 Clinical Pharmacology Program and 2 Surgery Branch, Center for Cancer.

NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.

1 Antiretroviral Therapy in HIV-infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.

Assistant Professor of Medicine Dana-Farber Cancer Institute

No prior therapy with PI

Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.

Drugs in the Body (1) Recurrence Relations A patient is given an initial dose of 50mg of a drug. Each hour the patient is given a 20mg tablet of the.

Dosing Regimen Individualization Body Size Variability in Body Size Does one size fit all ? If body size is outside the range  25% of normal (for 70.

Methodology. Patients Women with progressive metastatic breast cancer that overexpressed HER2 who had not previously received chemotherapy for metastatic.

Introduction The following procedure is for the reconstitution of aldoxorubicin drug product for use in the ALDOXORUBICIN-P3-STS-01 study. The reconstitution.

Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 10 Dosage Problems for Infants and Children.

Use of Safety Monitoring Flow Sheets. Background  Flow sheets can serve as useful tools  Not required but recommended  Tailor for ease of use AND usefulness.

Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.

Malattia HER-2 positiva Terapia adiuvante: quesiti irrisolti e nuovi studi U.O. di Oncologia Medica “Sandro Pitigliani” Dipartimento di Oncologia USL 4.

1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.

Dimensional Analysis and Conversion Factors. What the heck is a conversion factor? We use conversion factors to move from one unit of measurement to another.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,

Adult and Pediatric Dosages Based on Body Surface Area

TRAIN-2 (BOOG ): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC CCO Independent Conference Highlights*

Allie punke pharmcokinetics Allie punke

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Tab. 1 – Characteristics of patients

Medical Dosage Calculations A Dimensional Analysis Approach

Medical Dosage Calculations A Dimensional Analysis Approach

Clinical Calculation 5th Edition

Pharmcokinetics Allie punke.

Allie Punke Pharmacokinetics Allie Punke

Untch M et al. Proc SABCS 2010;Abstract P

Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Dr Axel Walther Head of Research Bristol Cancer Institute UK

Switch to ATV- or ATV/r-containing regimen

Telaprevir in Treatment Experienced GT-1 PROVE3

Flow chart patient inclusion.

Bv+Bs regimen schedule.

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

LINDA S. SNYDER, M.D., RUSSELL I. HEIGH, M.D., MONTE L. ANDERSON, M.D.

Dosage Calculation of Critical Care Medications: mcg/kg/min

Current standard of care treatment protocols for LN induction therapy.

ACETAMENOPHEN TOXICITY

Presentation transcript:

 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17): 1098 (letter)

 Case Example:  Female patient; weight 163 lb, Height 5’5”  On regimen:  Doxorubicin 40-60m 2 I.V ( DAY 1)  Cyclophosphamide 600mg/ m 2 I.V  Followed By:  Paclitaxel 175mg/m 2 IV over 3 hours  Repeat every 21 days for four cycles

 √  m 2 is BSA  40mg X 1.84 m 2 = 73.6mg  600mg X 1.84 m 2 = 1104mg  175mg X 1.84m 2 = 322mg 65 X

 Trastuzumab- given following completion of anthracycline therapy  Initial loading dose 8mg/kg infused over 90 minutes  Maintenance dose 6 mg/kg infused over minutes every three weeks for total therapy duration of 52 weeks

 Pt weight is 163 lb  1kg= 2.2lb  163lb = 73.9 kg 2.2 8mg X 73.9 = 591.2mg ( as loading dose infused over 90 minutes) 6mg X 73.9 = 443.4mg ( as maintenance dose infused over 30 to 60 minutes every three weeks)

 Monitoring Parameters!!!  CBC with differential  Platelet count  Liver function tests ( bilirubin, AST, ALT, alkaline phosphatase)  Cardiac function ( baseline, periodic and follow up) ECG, Left Ventricular ejection Fraction